The Role Of Interleukin (IL)-27 In The Endogenous Anti-tumour Immune Response And The Use Of An IL-27 Agonist As A Cancer Therapeutic.
Funder
National Health and Medical Research Council
Funding Amount
$473,960.00
Summary
Our data in mice suggest that immune cell signalling protein, interleukin (IL)-27, enhances anti-tumour immune responses and slows growth of mammary tumours and carcinogen induced sarcomas. This project aims to test how IL-27 promotes protective anti-tumour immune responses and to develop a modified IL-27 protein that will be tested as a cancer therapeutic in mice. This will be the first study to examine IL-27 function using physiological tumour models and may provide proof of concept for a new ....Our data in mice suggest that immune cell signalling protein, interleukin (IL)-27, enhances anti-tumour immune responses and slows growth of mammary tumours and carcinogen induced sarcomas. This project aims to test how IL-27 promotes protective anti-tumour immune responses and to develop a modified IL-27 protein that will be tested as a cancer therapeutic in mice. This will be the first study to examine IL-27 function using physiological tumour models and may provide proof of concept for a new therapeutic strategy for some human cancers.Read moreRead less